Lexington backs Rosetta’s direct pharma deal

The life sciences-focused direct secondaries firm has purchased 20 assets thought to be worth $5-10m each with the backing of Lexington Partners.

0

To view this content you must sign in:

Not yet registered? Join today to access Secondaries Investor’s industry insights and updates.